Compare Charles River Laboratories Intl. Inc (CRL) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Exxon Mobil Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $228.95 (market cap $11.14B), while Exxon Mobil Corporation trades at $142.78 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 54× Charles River Laboratories Intl. Inc's market cap, and Exxon Mobil Corporation pays a 2.84% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | XOM | |
|---|---|---|
Market Cap | $11.14B | $601.39B |
Sector | Health | Energy |
52-Week High | $233.60 | $171.52 |
52-Week Low | $145.57 | $105.83 |
Enterprise Value | $14.00B | $640.62B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
ExxonMobil (XOM) trades at $144.51, up 4.1% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 7.76% and a solid balance sheet, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes, supporting positive sentiment.
XOM offers value with a consensus price target of $169.30, implying 17% upside, but faces risks from volatile oil prices and declining profit margins. Institutional buy ratings at 40.74% reflect cautious optimism, while technical indicators suggest near-term resistance at $146. Investors should weigh the strong cash flow and dividend against energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
